Fig. 3From: Distinct activity of the bone-targeted gallium compound KP46 against osteosarcoma cells - synergism with autophagy inhibitionThe gallium compound KP46 widely synergizes with the standard OS chemotherapeutic agent cisplatin. The two compounds were applied either alone or in combination at the indicated concentrations for 72 h continuous drug exposure. Cell viability was determined by an MTT-based survival assay. Dose-response curves at the left are compared to the respective combination indices (CI) calculated by CalcuSyn Software at the right panels. CI < 0.9 represents synergism, >1.1 antagonism and 0.9–1.1 (grey area) additive effectsBack to article page